Fig. 5.

IFN-γ–modified DCs attenuate EAE in an IL-27–dependent manner. (A) DCs were left untreated (DC-Unt) or treated with IFN-γ (DC-IFN-γ) and pulsed with MOG and were then transferred into syngeneic WT mice. As indicated, some mice were coinjected with neutralizing anti-IL-27 antibody together with IFN-γ-treated DCs. Five days later, the DC primed mice were immunized with MOG and monitored for EAE. (B) LN cells obtained 18 d after immunization from mice described in (A) above, were restimulated with MOG35–55 (20 μg/mL) for 72 h. Cell-free supernatants were assayed for IL-17 and IL-10 by ELISA. (C) Clinical scores of EAE in WT and IL-27R^−/− mice injected with IFN-γ–treated or –untreated DCs before MOG immunization. (D) LN cells from IFN-γ-modified DC-treated and control DC-treated WT and IL-27R^−/− mice were activated in vitro with MOG35–55 (20 μg/mL) for 72 h, and cell-free culture supernatants were assayed for IL-17 and IL-10 by ELISA. (E) Clinical scores of EAE in WT mice immunized with MOG and treated with MOG-pulsed DCs modified with IFN-γ or their unmodified counterparts. Arrow indicates time of DC injection (clinical score of ≥1.5).